<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127684">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01810575</url>
  </required_header>
  <id_info>
    <org_study_id>PR-13311</org_study_id>
    <nct_id>NCT01810575</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction</brief_title>
  <official_title>A Study to Assess the Relative Efficacy and Safety of a Single Dose of Alprostadil Cream Combined With 2 Concentrations of WC3036 Compared to Vehicle in Subjects With Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety &amp; efficacy of a single dose of alprostadil
      cream with 2 concentrations of WC3036 compared to vehicle alone in men with erectile
      dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Re-assessment of study
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Penile rigidity</measure>
    <time_frame>Visit 1 / Up to 5 days ± 3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>≥60% at base and tip of penis lasting for ≥ 5 minutes evaluated with RigiScan. Treatment visits will be separated by at least 2 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Penile rigidity</measure>
    <time_frame>Visit 2 / Up to 9 days ± 3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>≥60% at base and tip of penis lasting for ≥ 5 minutes evaluated with RigiScan.  Treatment visits will be separated by at least 2 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Penile rigidity</measure>
    <time_frame>Visit 3 / Up to 14 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>≥60% at base and tip of penis lasting for ≥ 5 minutes evaluated with RigiScan. Treatment visits will be separated by at least 2 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of erection</measure>
    <time_frame>Visit 1 / Up to 5 days ± 3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject description of quality of erection using non-validated questionnaire.  Treatment visits will be separated by at least 2 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of erection</measure>
    <time_frame>Visit 2 / Up to 9 days ± 3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject description of quality of erection using non-validated questionnaire.  Treatment visits will be separated by at least 2 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of erection</measure>
    <time_frame>Visit 3 / Up to 14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject description of quality of erection using non-validated questionnaire.  Treatment visits will be separated by at least 2 days.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>WC3036-11F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WC3036-12F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WC3036-13P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WC3036-11F</intervention_name>
    <description>330 mcg alprostadil per 100 mg cream; WC3036 at a concentration of 2.5% w/w</description>
    <arm_group_label>WC3036-11F</arm_group_label>
    <other_name>Treatment A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WC3036-12F</intervention_name>
    <description>330 mcg alprostadil per 100 mg cream; WC3036 at a concentration of 0.5% w/w</description>
    <arm_group_label>WC3036-12F</arm_group_label>
    <other_name>Treatment B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WC3036-13P</intervention_name>
    <description>100 mg cream; WC3036 at a concentration of 0.5% w/w.</description>
    <arm_group_label>WC3036-13P</arm_group_label>
    <other_name>Treatment C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subject aged 40 or older of any race

          -  History of ED (erectile dysfunction) of at least 3 months duration defined as
             inability to attain &amp; maintain an erection of the penis sufficient to permit
             satisfactory sexual intercourse

          -  Completed and signed informed consent prior to any study related procedures

        Exclusion Criteria:

          -  History/presence any significant disease that Investigator feels will interfere with
             course of the study

          -  Anatomic deformity of penis

          -  History/presence alcoholism or drug abuse/dependence within past 2 years (discretion
             of Investigator)

          -  Participation in investigational study drug trial within 30 days prior to
             randomization
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vilma Sniukiene, MD</last_name>
    <role>Study Director</role>
    <affiliation>Warner Chilcott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Study Site</name>
      <address>
        <city>Purchase</city>
        <state>New York</state>
        <zip>10755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>February 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
